These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20621254)

  • 1. The role of aldosteronism in causing obesity-related cardiovascular risk.
    Calhoun DA; Sharma K
    Cardiol Clin; 2010 Aug; 28(3):517-27. PubMed ID: 20621254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study.
    Hundemer GL; Agharazii M; Madore F; Vaidya A; Brown JM; Leung AA; Kline GA; Larose E; Piché ME; Crean AM; Shaw JLV; Ramsay T; Hametner B; Wassertheurer S; Sood MM; Hiremath S; Ruzicka M; Goupil R
    Circulation; 2024 Jan; 149(2):124-134. PubMed ID: 38031887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiovascular consequences of hyperaldosteronism.
    Rossi GP; Seccia TM; Maiolino G; Cesari M
    Ann Endocrinol (Paris); 2021 Jun; 82(3-4):174-178. PubMed ID: 32192789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Risk in Primary Hyperaldosteronism.
    Prejbisz A; Warchoł-Celińska E; Lenders JW; Januszewicz A
    Horm Metab Res; 2015 Dec; 47(13):973-80. PubMed ID: 26575306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone and cardiovascular disease.
    Gaddam KK; Pimenta E; Husain S; Calhoun DA
    Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salt Appetite and its Effects on Cardiovascular Risk in Primary Aldosteronism.
    Adolf C; Schneider H; Heinrich DA; Handgriff L; Reincke M
    Horm Metab Res; 2020 Jun; 52(6):386-393. PubMed ID: 32252107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.
    Hundemer GL
    Curr Cardiol Rep; 2019 Jul; 21(9):93. PubMed ID: 31352525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperaldosteronism as a common cause of resistant hypertension.
    Calhoun DA
    Annu Rev Med; 2013; 64():233-47. PubMed ID: 23092384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk.
    Abad-Cardiel M; Alvarez-Álvarez B; Luque-Fernandez L; Fernández C; Fernández-Cruz A; Martell-Claros N
    Rev Esp Cardiol (Engl Ed); 2013 Jan; 66(1):47-52. PubMed ID: 23153688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Aldosterone on Cardiorenal and Metabolic Systems.
    Otsuka H; Abe M; Kobayashi H
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid antagonism and cardiac hypertrophy.
    Nagata K
    Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosteronism and hypertension.
    Calhoun DA
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1039-45. PubMed ID: 17699324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salt, aldosterone and hypertension.
    Pimenta E; Gordon RD; Stowasser M
    J Hum Hypertens; 2013 Jan; 27(1):1-6. PubMed ID: 22785050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan.
    Ohno Y; Sone M; Inagaki N; Yamasaki T; Ogawa O; Takeda Y; Kurihara I; Itoh H; Umakoshi H; Tsuiki M; Ichijo T; Katabami T; Tanaka Y; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Okamura S; Miyauchi S; Fukuoka T; Izawa S; Yoneda T; Hashimoto S; Yanase T; Suzuki T; Kawamura T; Tabara Y; Matsuda F; Naruse M; ;
    Hypertension; 2018 Mar; 71(3):530-537. PubMed ID: 29358460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.
    Monticone S; D'Ascenzo F; Moretti C; Williams TA; Veglio F; Gaita F; Mulatero P
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):41-50. PubMed ID: 29129575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular outcomes in patients with primary aldosteronism after treatment.
    Catena C; Colussi G; Nadalini E; Chiuch A; Baroselli S; Lapenna R; Sechi LA
    Arch Intern Med; 2008 Jan; 168(1):80-5. PubMed ID: 18195199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comorbidities in primary aldosteronism.
    Quinkler M; Born-Frontsberg E; Fourkiotis VG
    Horm Metab Res; 2010 Jun; 42(6):429-34. PubMed ID: 20049673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk].
    Widimský J
    Vnitr Lek; 2013 Jun; 59(6):501-4. PubMed ID: 23808747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.